Diamond Hill Capital Management LLC Investment Advisor Buys Shares of 1,945,121 Solventum Corporation $SOLV

Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Solventum Corporation (NYSE:SOLV) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,945,121 shares of the company’s stock, valued at approximately $150,066,000. Solventum makes up approximately 1.2% of Diamond Hill Capital Management LLC Investment Advisor’s investment portfolio, making the stock its 28th biggest position. Diamond Hill Capital Management LLC Investment Advisor owned 1.12% of Solventum as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of the business. Independent Franchise Partners LLP raised its position in Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after buying an additional 2,456,451 shares during the last quarter. Norges Bank bought a new position in Solventum during the 4th quarter valued at about $147,467,000. Diamond Hill Capital Management Inc. boosted its holdings in shares of Solventum by 152.2% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after acquiring an additional 1,272,921 shares during the last quarter. Boston Partners boosted its holdings in shares of Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after acquiring an additional 959,543 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Solventum in the second quarter worth approximately $61,460,000.

Analyst Ratings Changes

Several research firms have recently weighed in on SOLV. BTIG Research boosted their price objective on shares of Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Mizuho set a $113.00 target price on shares of Solventum in a report on Thursday, August 6th. Stifel Nicolaus lifted their target price on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wells Fargo & Company cut their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Solventum presently has a consensus rating of “Hold” and an average price target of $91.64.

Solventum Price Performance

NYSE SOLV opened at $88.53 on Monday. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $90.00. The firm has a market capitalization of $15.07 billion, a P/E ratio of 10.82, a PEG ratio of 1.14 and a beta of 0.60. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The company has a 50-day moving average price of $80.11 and a 200-day moving average price of $74.64.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts anticipate that Solventum Corporation will post 7.22 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.